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Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily. The activation of PPARs
by their speciﬁc ligands is regarded as one of the promising strategies to inhibit cancer cell growth. However, recent clinical trials
targeting several common cancers showed no beneﬁcial eﬀect when PPAR ligands are used as a monotherapy. Retinoid X receptors
(RXRs), which play a critical role in normal cell proliferation as a master regulator for nuclear receptors, preferentially form
heterodimers with PPARs. A malfunction of RXRα due to phosphorylation by the Ras/MAPK signaling pathway is associated with
the development of certain types of human malignancies. The activation of PPARγ/RXR heterodimer by their respective ligands
synergistically inhibits cell growth, while inducing apoptosis in human colon cancer cells when the phosphorylation of RXRα was
inhibited. We herein review the synergistic antitumor eﬀects produced by the combination of the PPAR, especially PPARγ, ligands
plus other agents, especially retinoids, in a variety of human cancers. We also focus on the phosphorylation of RXRα because the
inhibition of RXRα phosphorylation and the restoration of its physiological function may activate PPAR/RXR heterodimer and,
therefore, be a potentially eﬀective and critical strategy for the inhibition of cancer cell growth.
Copyright © 2008 M. Shimizu and H. Moriwaki. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
members of a superfamily of nuclear hormone receptors
comprising three isoforms, PPARα,P P A R β/δ,a n dP P A R γ,
which act as ligand-activated transcription factors. PPARs
play key roles in energy homeostasis by modulating glu-
cose and lipid metabolism and transport. Through these
metabolic actions, PPARs can regulate cell proliferation,
diﬀerentiation and survival [1, 2]. PPARs also control
immune and inﬂammatory responses [3]. Because these
physiological activities of PPARs are closely associated
with normal cell homeostasis, the aberrant expression and
function of PPARs have been observed in a variety of
human malignancies. Moreover, these reports also suggest
the possibility that targeting PPARs might be a critical
strategy for inhibiting the development and growth of
cancers. Indeed, numerous in vivo and in vitro studies have
demonstrated that PPAR agonists, especially, PPARγ ligands
can inhibit cell growth, cause apoptosis, and thus exert
antitumor eﬀects in various types of human malignancies
[4–6]. Based on the antigrowth and prodiﬀerentiation action
of PPARs, several clinical studies have been conducted using
the PPAR ligands in human cancers. However, with the
exception of a small trial on liposarcomas, the clinical trials
have so far indicated that the PPAR agonists may not be
useful as a monotherapy for advanced malignancies [7–
10].
On the other hand, recent preclinical studies show
absorbing evidence that the combined treatment with PPAR
ligands plus a variety of other agents can cause a synergistic
eﬀect to inhibit growth in cancer cells. For instance, we
recently found that the activation of PPARγ/RXR het-
erodimer by their respective ligands synergistically inhibited
cell growth and induced apoptosis in human colon cancer
cells [11]. Therefore, the aim of this paper is to review the
possibility that the combined usage of the PPAR ligands
with other agents may therefore be a critical strategy for
the treatment of certain types of human cancers. We also
review the signiﬁcance of the aberrant phosphorylation of2 PPAR Research
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Figure 1: PPAR activation pathway and transcriptional regulation
of target genes. After ligand binding, PPARs form heterodimers
with RXR in the nucleus. The PPAR/RXR heterodimers interact
with transcriptional coactivators (CoActs) and bind to sequence
speciﬁc PPRE located in the target genes that control glucose and
insulin homeostasis, lipid metabolism, inﬂammation, and cellular
diﬀerentiation. L: ligand.
retinoid X receptor (RXR), which is a heterodimeric partner
for PPARs, as described in the next section.
2. RXRs AND PPARs
RXRs and retinoic acid receptors (RARs), both of which
are composed of three subtypes (α, β,a n dγ), are also
members of the nuclear hormone receptor superfamily. The
ligands for RXRs and RARs are the retinoids, a group of
structural and functional analogues of vitamin A, and the
retinoids have a profound eﬀect on such cellular activities
as growth, diﬀerentiation, apoptosis, and morphogenesis
primarily through binding to RXRs and/or RARs. A small
portion of dietary retinoids is converted to retinoic acid
(RA), which is an active metabolite of the retinoids. RXR
is speciﬁc for the 9-cis RA, while RAR binds both 9-
cis RA and all-trans RA (ATRA). The nuclear retinoid
receptors are ligand-dependent transcription factors that
bindtotheretinoicacidreceptorresponsiveelement(RARE)
and retinoid X receptor responsive element (RXRE), which
are present in the promoter regions of retinoid responsive
target genes, thereby modulating the gene expression [12,
13]. Other nuclear receptors, including PPARs, also require
RXR as a heterodimeric partner in order to exert their
function. After ligand binding, PPARs can regulate target
gene expression by binding to the peroxisome proliferator
responsive element (PPRE) in target genes as a heterodimer
with RXRs (see Figure 1)[ 14, 15]. Therefore, RXRs play
a fundamental role in controlling normal cell proliferation
and metabolism and act as a master regulator of nuclear
receptors. Among the retinoid receptors, RXRα is thought to
be one of the most important receptors with respect to the
regulation of the essential eﬀects of cell activities.
3. STRUCTURE OF RXRα AND SIGNIFICANCE OF
RXRα PHOSPHORYLATION
RXRs have a variable N-terminal domain (A/B domain;
AF-1), a highly conserved DNA-binding domain (DBD),
a nonconserved hinge, and a moderately conserved C-
terminus including the ligand-binding domain (LBD). Tran-
scriptional activation is mediated by LBD, which contains four
more-or-less overlapping surfaces: a ligand-binding pocket for
the binding of small, lipophilic molecules, a transactivation
domain (AF-2 or helix 12), a cofactor binding surface, and
a dimerization surface [16]. Recent studies revealed that
phosphorylation processes are critical for the transcrip-
tional activity of RAR/RXR heterodimers. Bruck et al. [17]
reported that the activation of c-Jun N-terminal kinases
(JNKs) induces phosphorylation of both at three residues
(serine 61, serine 75, and threonine 87) located in the
N-terminal AF-1 domain and one residue (serine 265) in
the Omega loop in LBD (AF-2 domain) of RXRα.T h e
RA-induced phosphorylation of the same three residues in
the AF-1 domain is required for the cooperation of RXRα
with RARγ for maximal transcriptional activity [18]. The
phosphorylation of RXRα in its N-terminal domain plays
a role to activate a subset of RA-responsive genes and for
the antiproliferative eﬀect of RA [19]. These ﬁndings suggest
that RXRα “positively” regulates the transactivation of target
genes through phosphorylation [20].
On the other hand, there are some contrary reports
which show the phosphorylation of RXRα to “negatively”
modulate the function of its heterodimeric binding partners.
Indeed, MAPK-mediated phosphorylation of the RXRα LBD
impairs the transcriptional activity of RXR/RAR [21, 22]
and RXR/vitamin D3 receptor (VDR) [23]. These “negative”
eﬀects of RXRα via its phosphorylation might be associated
with certain types of human diseases, including cancer
[20]. In the next section, we review the speciﬁc roles of
the aberrant phosphorylation of RXRα in carcinogenesis,
especially focusing on the development of hepatocellular
carcinoma (HCC).
4. RXRα PHOSPHORYLATION AND CANCER
Abnormalities in the expression and function of retinoids
and their receptors play an important role in inﬂuencing the
development of various human malignancies and, therefore,
might be critical targets for cancer chemoprevention and/or
chemotherapy [24]. Speciﬁcally, we previously reported that
hepatocarcinogenesis is accompanied by an accumulation
of the phosphorylated (i.e., inactivated) form of RXRα and
the inhibition of RXRα phosphorylation may thus be an
eﬀective strategy for preventing the development of HCC.
Initially, we showed that the RXRα protein is anomalously
phosphorylated at a speciﬁc site of the serine/threonine
residues and is accumulated both in human HCC tissue as
well as in HCC cell lines [22]. Phosphorylation at serine
260 of RXRα, a consensus site of mitogen-activated protein
kinase (MAPK), is closely linked to its retarded degradation,
low transcriptional activity, and the promotion of cancer
cell growth, and the abrogation of phosphorylation byM. Shimizu and H. Moriwaki 3
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Figure 2:AschematicrepresentationofRXRαphosphorylationinHCCcells.Innormalhepatocytes,whentheligand(retinoid)bindstoand
activates RXRα, the receptor becomes able to heterodimerize with other nuclear receptors, including RAR, and then activates the expression
of the target genes, which may regulate normal cell proliferation and diﬀerentiation, by binding to the speciﬁc responsive element. In HCC
cells, the Ras/MAPK pathway is highly activated and phosphorylates RXRα at serine residues, thus impairing the functions of the receptor.
Therefore, the accumulated p-RXRα interferes with the remaining normal RXRα, presumably, in a dominant negative manner, thereby
playing a critical role in the development of HCC. L: ligand. Ub: ubiquitin.
MAPK-speciﬁc inhibitors restores the degradation of RXRα
in a ligand-dependent manner [22, 25]. In addition, the
phosphorylated form of RXRα (p-RXRα) is also resistant to
ubiquitination and subsequent proteasome-mediated break-
down in both human HCC tissues and a human HCC cell
line, whereas RXRα protein is unphosphorylated and highly
ubiquitinated in the normal liver and in nonproliferating
hepatocyte cultures [26]. The phosphorylation of RXRα
abolishes its ability to form heterodimers with RARβ,t h u s
resulting in the loss of cell growth control, resistance
to retinoids, and the acceleration of cancer development
[27]. These ﬁndings suggest that the accumulation of p-
RXRα (i.e., nonfunctional RXRα), which can escape from
the proteasome-mediated degradation system, may interfere
with the function of normal RXRα in a dominant-negative
manner, thereby playing a critical role in the development of
HCC (see Figure 2)[ 28].
In addition to HCC, a malfunction of RXRα due to
a posttranslational modiﬁcation by phosphorylation is also
associated with the development of other types of human
malignancies. We recently reported that RXRα protein is
highlyphosphorylatedandalsoaccumulatedinhumancolon
cancertissuesamplesaswellashumancoloncancercelllines,
while the levels of expression of p-RXRα do not increase in
normal colonic epithelial cells; RXRα protein is phospho-
rylated in 75% of colorectal cancer tissues when compared
with corresponding normal colon epithelial tissues [11].
Similar results have also been observed in human pancreatic
cancer (manuscript in preparation). Moreover, Kanemura et
al. [29] reported the abnormal phosphorylation of RXRα
proteintoplayaroleintheenhancementofcellproliferation,
whileproducinganantiapoptoticeﬀect,andalsopresumably
acquiring RA-resistance in HL-60R human leukemia cells. In
addition to these malignancies, full-length RXRα is anoma-
lously phosphorylated and accumulated in leiomyoma when
compared to myometrial cells and this is associated with a
resistance to ligand-mediated ubiquitination and a delay in
the receptor proteolytic degradation [30].
What are the precise mechanisms by which phosphoryla-
tion of RXRα loses its transcriptional activity? Recent studies
indicate that the phosphorylation of RXRα can regulate
the function of its heterodimeric binding partners. For
instance, Solomon et al. [23] reported that phosphorylation
of RXRα at serine 260, which is located in the Omega
loop of the LBD, results in the attenuation of ligand-
dependent transactivation by RXR/VDR complex in human
keratinocytes, thus resulting in the induction of malignant
transformation. The residues located in the AF-2 domain are
also phosphorylated in response to stress agents, including
JNKs and MKK4/SEK1 [21, 31], among which serine 265
located in the Omega loop [31], and these phosphorylations
are closely linked to inhibit the transcription of RA target
genes. The phosphorylation of RXRα at serine 260 is also
associated with retinoid resistance [22, 27]. Therefore, these
ﬁndings indicate that RXRα phosphorylation, which occurs
at speciﬁc residues located in the Omega loop of the LBD,
is apparently associated with a malfunction in the retinoid-
dependent signaling pathway. The Omega loop, located
between helices H1 and H3, is a very ﬂexible and dynamic
region that moves substantially during the conformational
rearrangement that accompanies ligand binding to the LBD
[32]. It has therefore been proposed that phosphorylation
of the residues in this loop might alter the dynamics of
this region and create conformational changes within the4 PPAR Research
LBD, thus disrupting the interactions with coactivators and
therefore inhibiting the activation of RA-responsive genes
[17, 33].
5. PHOSPHORYLATED RXRα IS A CRITICAL TARGET
F O RCA N C E RT R E A T M E N T
Theaboveﬁndingssupportthepossibilitythattheinhibition
of RXRα phosphorylation and the restoration of its physi-
ological function as a master regulator of nuclear receptors
must be an eﬀective strategy for controlling cell growth in
various types of human cancers. It has been shown that
the new synthetic retinoid, acyclic retinoid (ACR, NIK-
333: Kowa Pharmaceutical Company Ltd., Tokyo, Japan),
which was originally developed as an agonist for both
RXR and RAR [34, 35], can restore the function of RXRα
by inactivating the Ras-Erk signaling system and thereby
inhibitingRXRαphosphorylation[25].Practically,thisagent
has demonstrated several beneﬁcial eﬀects in experimental
studies both in vivo and in vitro. For instance, ACR inhibited
chemically induced hepatocarcinogenesis in rats as well as
spontaneously occurring hepatoma in mice [36]. This agent
also inhibited growth and induced apoptosis in human
HCCderived cells [37–42]. Similar growth inhibitory eﬀects
are also observed in other types of human cancer cells,
such as squamous cell carcinoma or leukemia cells [43,
44].
In addition, we also conﬁrmed the chemopreventive
eﬀect of ACR on recurrent and second primary HCCs in
patients who received anticancer treatment for an initial
HCC in a double-blind and placebocontrolled clinical study.
Namely, the oral administration of ACR for 12 months
signiﬁcantly reducedthe incidence of posttherapeutic recur-
rence of HCC and improved the survival rate in patients who
underwent potentially curative treatments, without causing
any severe adverse eﬀects [45–47]. These ﬁndings suggest
that ACR is a promising agent for the chemoprevention
of HCC and that p-RXRα may be a critical target for the
chemoprevention and/or treatment of some types of human
cancers, including HCC, which show the accumulation of p-
RXRα protein.
6. SYNERGY BETWEEN PPARγ LIGANDS AND
RETINOIDS IN CANCER
Since RXR forms a permissive heterodimeric complex with
PPAR, and the activation of PPARγ exerts antigrowth
eﬀects in cancer cells [4–6], it seems to be reasonable
that the combination of RXR and PPARγ agonists may
oﬀer new therapeutic strategies for various types of human
malignancies. Firstly, Tontonoz et al. [15] reported that
the combined use of PPARγ and RXRα speciﬁc ligands is
able to trigger terminal diﬀerentiation of primary human
liposarcoma cells in vitro. This result suggests that the
combination of these ligands may be a useful therapy for
the treatment of liposarcoma [15]. Beneﬁcial eﬀects for the
combined treatment with PPAR ligands plus retinoids are
extensively reported in preclinical studies of the hematologic
malignancies [48–51]. Therefore, the combination of PPARγ
ligand with RXR agonist or RAR agonist can enhance
the diﬀerentiating and growth-inhibitory eﬀects in human
leukemia cells [48]. The combination of PPARγ ligand,
ciglitazone, and ATRA synergistically reduces the cell growth
r a t e sa n dc e l lc y c l ea r r e s ta tt h eG 1p h a s ei nH L - 6 0h u m a n
leukemia cells, and this is associated with synergistic upregu-
lationofPTENexpression[49].Thecombinationof9-cisRA
andPPARγ ligandshowssigniﬁcantsynergisticeﬀectsforthe
induction of apoptosis in multiple myeloma cells [50]. These
reports suggest that the combination of PPARγ ligands plus
retinoids holds promise as a novel therapy for some types
of hematologic malignancies by activating the transcription
of target genes that control apoptosis and diﬀerentiation in
these malignant cells.
In addition to the hematologic malignancies, a number
of preclinical studies indicate the preferable eﬀects by the
combinationofPPARligandsplusretinoidsontheinhibition
of cell growth in solid malignancies, especially in breast
caner [52–55]. For instance, Rubin et al. [55] showed that
a combination of ligands for PPARγ and RXR inhibits
breast aromatase expression induced by tumor-derived fac-
tors. Because aromatase activates estrogen biosynthesis, the
combination of these ligands may be able to ﬁnd utility in
thetreatment of estrogen-dependent carcinogenesis, such as
breast cancer and endometrial cancer [56]. The combination
of RXR ligand with ciglitazone also cooperatively inhibits the
growth of breast cancer and lung cancer cells by activating
theRAREpromoteractivityandinducingRARβ,whichplays
a critical role in mediating the growth-inhibitory eﬀects
of retinoids in various cancer cells [57]. In addition, the
synergistic or cooperative eﬀect of RXR and PPARγ agonists
for growth inhibition and apoptosis induction is found in
colon cancer cells [11, 58]. The detailed eﬀects of PPARγ
ligands plus retinoids to inhibit growth in colorectal cancer
cells are discussed in the next section.
Whatarethemolecularmechanismsbywhichthecombi-
nation of PPARγ ligands and retinoids synergistically induce
anticancer eﬀects? Yang et al. [59] reported that the PPARγ
and RXR ligands have been shown to diﬀerentially recruit
subsets of transcriptional coactivators (i.e., p160 by RXR and
DRIP205 by PPARγ) to the receptor complex, thus leading
toanenhancedtranscriptionalactivationandcellulareﬀects.
The transcriptional activity of PPRE is additively induced by
treatment with a PPARγ activator plus 9-cis RA, and RXRα
accumulation, by inhibiting its degradation due to the pro-
teasome system, therefore contributes to the enhancement
of PPARγ/RXR activation [60]. The transactivation of the
PPRE by PPARγ/RXR heterodimer enhances the expression
of the glutathione S-transferase gene, which is responsible
for the cellular metabolism as well as the detoxiﬁcation of
several xenobiotics and carcinogenic compounds [61]. The
ﬁndings of these reports suggest that the accumulation of
the unphosphorylated form (i.e., functional form) of RXRα
activates the transcriptional activity of PPRE and thereby
enhances the expression of important target genes. The
signiﬁcance of the restoration of RXRα by inhibiting its
aberrant phosphorylation is reported in the studies using the
cell lines of HCC [22, 28], leukemia [29], and colon cancer
[11], as discussed below.M. Shimizu and H. Moriwaki 5
7. SYNERGY BETWEEN PPARγ LIGANDS AND
RETINOIDS IN COLORECTAL CANCER
Among the PPAR targeting therapies, the activation of
PPARγ byitsligandisregardedasapotentiallyusefulstrategy
for the chemoprevention and/or treatment of colorectal
cancer because many in vivo and in vitro preclinical studies
have demonstrated that PPARγ ligands can inhibit cell
growth, cause apoptosis, and thus exert antitumor eﬀects
in this malignancy [5, 62–65]. As a result, there has been
considerable interest in utilizing the combination of ligands
for PPARγ and RXR for the prevention and treatment
of colorectal cancer. In fact, it has been reported that in
human colon cancer cells the combination of the RXR
and PPARγ agonists produces greater eﬃcacy in growth
inhibition than either single agent alone, and this is
associated with a cooperative reduction in the levels of
cyclooxygenase-2 (COX-2) expression and prostaglandin E2
(PGE2) synthesis [58]. The simultaneous exposure of HT-
29 human colon cancer cells to ciglitazone and 9-cis RA
results in an increased apoptotic eﬀect and greater inhibition
of COX-2 expression, in comparison to cells treated with
either ciglitazone or 9-cis RA alone [66]. We recently
reported that the combination of 9-cis RA and ciglitazone
causes a synergistic inhibition in the growth of human
colon cancer Caco2 cells, which express high levels of p-
RXRα protein, and this is associated with the induction of
apoptosis and inhibition in the expression of both COX-
2 and c-Jun proteins and mRNAs. The combination of
these agents has a synergistic eﬀect in increasing the PPRE
activity and decreasing the AP-1 activity. However, we
should emphasize that these preferable eﬀects are observed
when the phosphorylation of RXRα protein is inhibited
[11]. Therefore, the inhibition of the phosphorylation of
this protein appears to play a critical role in inducing
the synergistic growth inhibitory eﬀect in colon cancer
cells.
The above ﬁndings indicate that the activation of
the RXR/PPARγ heterodimer by their speciﬁc ligands can
decrease the expression of COX-2, which is one of the main
mediatorsintheinﬂammatorysignalingpathway.Thisseems
to be signiﬁcant because COX-2 plays a critical role in
the development of colorectal cancer and might, therefore,
be an important molecular target for colorectal cancer
prevention and treatment [67]. Recent studies have revealed
2, 4, 6-trinitrobenzene sulfonic acid-induced colitis to be
signiﬁcantly reduced after the administration of both PPARγ
and RXR agonists, and this beneﬁcial eﬀect is reﬂected
by the reduction in the NF-κB DNA binding activity in
the colon [68]. The inhibition of the β-catenin mediated
pathway, which promotes the development of colon cancer
and is stimulated by COX-2 as well as PGE2 [69, 70], by
nonsteroidal anti-inﬂammatory drugs, requires a high-level
expression of RXRα and PPARγ [71]. Therefore, the activa-
tionoftheRXR/PPARγ heterodimerbythecoadministration
of their ligands is clinically useful for the prevention and/or
treatment of colon cancer as well as colonic inﬂammation
[72], due to their synergistic eﬀects on the COX-2/PGE2
axis.
8. SYNERGY BETWEEN PPARs LIGAND AND THE
OTHER DRUGS EXCEPT FOR RETINOIDS IN CANCER
In addition to the retinoids, the synergistic eﬀects of PPARγ
ligands with other agents have also been reported by many
investigators. Girnun et al. [73] found that agonist activation
of PPARγ synergistically increases the growth-inhibitory
eﬀect of the platinum-based drugs cisplatin and carboplatin
in several diﬀerent types of cancers in both in vivo and in
vitro studies. This synergy is associated with the reduction
of multiple members of the metallothionein gene family
expression, which play a role in the resistance of certain
cancers to platinum-based drugs [74]b yP P A R γ [73]. The
synergistic or enhancing eﬀects induced by the combination
of PPAR ligands plus other conventional chemotherapeutic
agents to inhibit cell growth are also reported in several types
of cancer cells [75–77]. In addition, it is also reported that
the histone deacetylase (HDAC) inhibitors have a synergistic
eﬀect with the thiazolidinediones in the activation of PPARγ
target genes [78]. In studies using cancer cells, the com-
bination treatment using the PPARγ agonist pioglitazone
and the HDAC inhibitor valproic acid has been reported to
be more eﬃcient at inhibiting prostate tumor growth than
each individual therapy alone [79]. An enhanced growth
inhibition is observed when neuroblastoma cells are treated
with a PPARγ ligand and a HDAC inhibitor, thus suggesting
that a combination therapy to treat neuroblastoma might
prove more eﬀective than using either agent alone [80].
These ﬁndings suggest that a combination therapy using
PPARγ agonists and HDAC inhibitors might therefore be
potentially eﬀective for the treatment of some types of
human malignancies.
Recently, molecular-targeted therapy is attractive as a
new eﬀective strategy to inhibit the growth of cancer cells,
and therefore, the combination therapy using such speciﬁc
molecular-targeting agents plus PPAR ligands may become
an important regimen in near future. For instance, the
proteasome inhibitor bortezomib, which can inhibit the
NF-κB activity, augments the antiproliferative eﬀects of
the PPARγ agonist rosiglitazone in human melanoma cells
[81]. The dual ligand speciﬁc for PPARα/γ synergistically
enhanced the antiproliferative and proapoptotic eﬀect of
imatinib, a speciﬁc inhibitor of BCR-ABL tyrosine kinase,
in Philadelphia chromosome-positive lymphocytic leukemia
and chronic myelogenous leukemia blast crisis cell lines
[82, 83]. The growth inhibitory eﬀects by geﬁtinib, an EGFR
tyrosine kinase inhibitor, on the human lung cancer cell line
are potentiated by the treatment with PPARγ ligand, and this
is associated with an increase in the expression of PTEN, but
a reduction in the expression of p-Akt [84]. It is interesting
to note that the activation of PPARγ by its ligand causes a
dramaticinhibitionofthetyrosinephosphorylationofHER2
and HER3 receptors, the other member for the EGFR family
of receptor tyrosine kinases (RTKs), in human breast cancer
cells [85]. The PPARγ ligand also blocks phosphorylation of
other member of RTKs, such as IGF-1R, thereby suppressing
the proliferation of breast cancer cell lines [85]. These ﬁnd-
ings may explain the mechanisms in regard to precisely how
the PPARγ ligands can enhance the eﬀects of speciﬁc RTK6 PPAR Research
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Figure 3: A hypothetical schematic representation of the synergistic anticancer eﬀects of the combination of PPAR ligands plus other agents.
When PPARs are activated by ligand binding, they are able to heterodimerize with RXR and activate the target gene expression by binding to
the PPRE element. Therefore, the retinoids which bind to RXR may be the most preferable partner for the PPAR agonists (A). However, in
some types of cancers, the MAPK pathway phosphorylates RXRα, and the accumulated nonfunctional p-RXRα interferes with the function
of the remaining normal RXRα, thereby promoting the growth of cancer cells. The activation of RTKs by their speciﬁc ligands (growth
factors) can play a critical role in the stimulation of the MAPK pathway. Therefore, the agents which target the activation of RTKs (B) and/or
the MAPK pathway (C) restore the function of RXRα as a master regulator of nuclear receptors in cancer cells and this will support the
synergistic growth inhibition by PPAR and RXR ligands in cancer cells. The HDACs enforce a tight chromatin structure and thereby repress
the transcription of target genes controlled by PPAR/RXR. Therefore, the combination of a PPAR agonist plus an HDAC inhibitor is more
eﬃcient to inhibit the growth of cancer cells (D). Finally, the conventional chemotherapeutic agents also cause synergistic or enhancing
eﬀects to inhibit cancer cell growth by the combination of PPAR ligands (E). L: ligand.
inhibitors, although some other molecules may also play
ar o l e .
9. IS PPAR PHOSPHORYLATION
ASSOCIATED WITH CANCER?
As mentioned above, a malfunction of RXRα due to
phosphorylation is associated with cancer cell growth and
retinoid resistance [11, 22, 27, 29]. However, a question
which arises here is whether the phosphorylation of PPARs
also plays a role in carcinogenesis and/or resistance to the
PPAR ligands. Recent studies have shown that PPARs are
phosphoproteins,andtheirtranscriptionalactivityisaﬀected
by several kinases, including ERK/MAPK, both in a ligand-
dependent and/or -independent manner [86]. Although the
signiﬁcance of the PPARs phosphorylation in cancer has not
been clariﬁed, at least in PPARγ, the transcriptional activity
of this receptor is inhibited by phosphorylation [87–89].
Extracellular signals that activate intracellular phosphory-
lation pathways can inﬂuence the degradation process of
PPARγ [89, 90]. These reports may suggest that as well as
RXRs [22, 27], the phosphorylation-mediated inhibition of
transcriptional activity of PPARs is associated with cancer
[20]. Hedvat et al. [91] conducted an interesting study,
reporting that the activation of PPARγ is sustained by the
presence of HER-kinase inhibitor, suggesting that HER-
kinase and its downstream ERK/MAPK pathway phos-
phorylate PPARγ and, therefore, abrogate the eﬀects of
PPARγ activity through degradation of this nuclear receptor.
In this study, the inhibition of HER-kinase activity was
suﬃcient to inhibit PPARγ protein degradation [91]. These
ﬁndings suggest that, in future studies, the combination of
PPARγ/RXR ligands plus a speciﬁc agent which targets the
RTKs and/or Ras/MAPK signaling pathway may therefore
become a promising strategy to inhibit the growth of cancer
cells by inhibiting the phosphorylation of PPARs/RXRs.
10. CONCLUSION
The combined use of two or more agents is often advan-
tageous since it may permit to lower the clinical dosages,
thereby decreasing the overall toxicity, and thus providing
the potential for synergistic eﬀects between agents. In this
review, we made an attempt to show the synergism between
PPARγ agonists and other agents (see Figure 3). Among such
preferable candidates, retinoids seem to be the best partner
of PPARγ ligands in order to exert synergistic antitumor
eﬀects. However, phosphorylation of RXRα represses the
PPARγ/RXR-dependentanticancereﬀects.Insomecases,the
inhibition of PPAR phosphorylation may also support the
antitumor function of these nuclear receptors. In addition,
we should keep in mind the fact that the encouraging resultsM. Shimizu and H. Moriwaki 7
obtained from the combined use of PPARγ agonists plus
other agents have been exclusively reported in preclinical
studies, and PPAR agonist monotherapy did not achieve a
signiﬁcant result for advanced malignancies in clinical trials,
except for a small trial on liposarcomas [7–10]. Therefore,
it might be expected that some combination with other
agents may lead to breakthrough in the clinical application
of PPARγ agonists for chemoprevention and/or treatment of
malignancies.
In conclusion, the combination treatment using the
PPARγ agonists and other agents might be an eﬀective and
promising strategy for chemoprevention and/or treatment
of various types of cancers. Future studies will be necessary
to improve the anticancer eﬃcacy of PPARγ agonist plus
retinoids by combining with appropriate speciﬁc kinase
inhibitors.
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PPRE: Peroxisome proliferator responsive element
RXR: Retinoid X receptor
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ERK: Extracellular signal-related kinase
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